secwatch.observer — SEC 8-K summary
======================================

Issuer:     IRONWOOD PHARMACEUTICALS INC (IRWD)
CIK:        0001446847
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001104659-23-115985
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ironwood Q3 total revenue $113.7M, GAAP diluted EPS $0.09 vs $0.28 YoY
----------------------------------------------------------------------

- Total revenues $113.7M (up 5% YoY); GAAP net income $15.3M, diluted EPS $0.09 vs $0.28.
- LINZESS U.S. net sales $279M (+7% YoY); prescription demand +8%.
- Positive final data from Phase II STARS Nutrition study of apraglutide in SBS-IF with CIC.
- Expects topline data for CNP-104 in primary biliary cholangitis in Q3 2024.
- Maintains full year 2023 guidance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1446847/000110465923115985/0001104659-23-115985-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1446847/000110465923115985/tm2330146d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-115985

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer